Panel: What does a ‘Trial Ready’ Therapeutic look like in 2026?

Determining trial readiness requires alignment across scientific, regulatory, and commercial stakeholders. This panel examines how early-stage developers can address common bottlenecks, optimize preclinical and translational strategies, and design clinical trials that meet expectations for safety, efficacy, and scalability. 

Key Takeaways: 

• Identify the scientific, operational, and regulatory markers of a trial-ready program 

• Address bottlenecks in preclinical validation and translational models 

• Select and validate biomarkers to guide patient selection and trial endpoints 

• Design clinical trials that align with stakeholder expectations 

• Integrate insights from investors, regulators, and clinicians to enhance program impact